- Drugs
- Friday, 22 May 2020
Hikma receives FDA approval for its generic Vascepa®
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has announced that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.
Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."
| Enquiries | |
| Hikma Pharmaceuticals PLC | |
| Susan Ringdal | +44 (0)20 7399 2760/ +44 7776 477050 |
| EVP, Strategic Planning and Global Affairs | |
| Steve Weiss | +1 732 720 2830/ +1 732 788 8279 |
| David Belian | +1 732 720 2814/+1 848 254 4875 |
| US Communications and Public Affairs |
Related Industry Updates
Verde Leaf™ Appoints Carl L. Powell as Chairman
May 05, 2020
North America Intravenous Immunoglobulin Market is expected to reach US$ 8,747.81 million by 2030
Oct 10, 2023
Osteonecrosis Treatment Market is expected to reach US$ 1,021.92 million by 2030
Dec 12, 2023
OTC Drug and Dietary Supplement Market Outlook, Geographical Segmentation, Industry Size & Share, Comprehensive Analysis to 2027
Sep 09, 2020
Asia Pacific Companion Animal Diagnostics Market Research Along With COVID-19 Impact Analysis, Advancement and Outlook 2027| Fujifilm Corporation, Skyla Corporation, Virbac
Jan 15, 2021
US Intravenous Immunoglobulin Market is expected to reach US$ 7,105.63 million by 2028
Apr 19, 2023
Ferrocene Market Manufacturers, Industry Demand, Size, Share, Growth and Forecast Analysis to 2027
Apr 26, 2021
Follow us on
